Data_Sheet_2_Causes of Death and Conditional Survival of Renal Cell Carcinoma.docx
Background: As conditional survival could provide more relevant prognostic information at each follow-up time, the present study aimed to assess conditional overall survival (COS) based on two cohorts and assess the risks of death due to renal cell carcinoma (RCC) vs. other causes.
Methods: The Fudan University Shanghai Cancer Center (FUSCC) and Surveillance, Epidemiology, and End Results (SEER) database were used as the source of data for our analysis. COS and cancer-specific survival were evaluated using the Kaplan–Meier method.
Results: A total of 90,927 patients (SEER cohort = 88,807, FUSCC cohort = 2,120) were enrolled. Our results suggest that hazards of other causes-related death were always higher than that of cancer-specific death in low-risk RCC patients, but lower in metastatic RCC patients. It exceeded that of cancer-specific death by 8 years in high-risk RCC patients. Only in metastatic RCC patients, the COS improved markedly with survivorship increasing. After surviving 1, 2, 3, 4, and 5 years, the 5 years COS increased by +10, +18, +23, +29, and 35% (the observed 5 years OS: 12%), respectively.
Conclusions: COS can better help patients with metastatic RCC rather than other RCC patients. Additionally, COS brings optimism for metastatic RCC patients with expected poorer prognosis psychologically.
History
References
- https://doi.org//10.1634/theoncologist.2011-S2-45
- https://doi.org//10.1016/j.eururo.2012.04.049
- https://doi.org//10.1093/annonc/mdu259
- https://doi.org//10.18632/oncotarget.7511
- https://doi.org//10.6004/jnccn.2017.0100
- https://doi.org//10.1016/j.eururo.2012.02.057
- https://doi.org//10.1016/j.juro.2017.06.073
- https://doi.org//10.1016/j.juro.2018.06.030
- https://doi.org//10.1158/1078-0432.CCR-11-2663
- https://doi.org//10.1097/SLA.0000000000001527
- https://doi.org//10.1097/CAD.0000000000000335
- https://doi.org//10.3310/hta22060
- https://doi.org//10.1016/j.ejca.2014.04.009
- https://doi.org//10.18632/oncotarget.12920
- https://doi.org//10.1097/MD.0000000000005746
- https://doi.org//10.1016/j.ejca.2018.07.124
- https://doi.org//10.1016/j.eururo.2010.07.006
- https://doi.org//10.1016/S1470-2045(16)30408-9
- https://doi.org//10.1097/JTO.0000000000000472
- https://doi.org//10.1001/jamasurg.2017.1665